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Objective:  To investigate whether there is an association between use of cocaine, 
amphetamines, or psychedelics and psychotic symptoms.   
Method:  Cumulated data from a prospective, longitudinal community study of 2588 adolescents 
and young adults in Munich, Germany were used.  Substance use was assessed at baseline, 4-
year and 10-year follow-up using the Munich Composite International Diagnostic Interview; 
psychotic symptoms were assessed at 4-year and 10-year follow-up.  Multinomial logistic 
regression analyses, adjusted for sociodemographic factors, common mental disorders, other 
substance use, and childhood adversity (adjusted odds ratios, AOR), revealed associations 
between cocaine, amphetamine or psychedelic use and psychotic symptoms.   
Results:  Lifetime experience of psychotic symptoms was associated with lifetime use of 
cocaine (AOR 1.94; 95%CI 1.10-3.45), amphetamines (AOR 1.69; 95%CI 0.98-2.93), 
psychedelics (AOR 2.37; 95%CI 1.20-4.66) and all three substances (AOR 1.95; 95%CI 1.19-
3.18).    
Conclusion:  Associations between psychotic symptoms and use of cocaine, amphetamines, 
and/or psychedelics in adolescents and young adults call for further studies to elucidate risk 
factors and developmental pathways. 
Keywords:  Substance-Related Disorders, Cocaine, Amphetamine, Psychedelics, Psychoses 
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Significant Outcomes 
• After adjusting for potential confounding factors, use of cocaine, amphetamines or 
psychedelics was associated with psychotic symptoms. 
• Among a subgroup of persons without a mood or anxiety disorder, analysis revealed an 
association between use of cocaine, amphetamines or psychedelics and psychotic symptoms. 
Limitations 
• The low positive predictive value of the M-CIDI does not allow for analysis of psychotic 
disorders; analysis is limited to psychotic symptoms. 
• The relatively low prevalence of psychotic symptoms among this community sample limited 
the ability to analyse for a temporal relationship between substance use and psychotic symptoms. 
• Self-report of lifetime substance use and psychotic symptoms may lead to recall errors or 
erroneous information.
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1. Introduction 
Although the association of drug use with mood, anxiety and personality disorders has 
been well documented (1-3), there has been an increased interest in the risk of psychosis among 
those using illegal drugs.  Several clinical and community-based studies have demonstrated an 
association between cannabis use and psychotic symptoms (4-11).  Non-cannabis drug use has 
been examined among persons with established psychotic disorders (12,13) and psychotic 
symptoms (14-17).  Some of these studies demonstrate an association between use of stimulants 
and psychotic symptoms (12,15-17).  In investigating the temporal relationship between 
substance (e.g. cannabis, amphetamine, cocaine, psychedelics) use and onset of psychotic 
symptoms, several studies report that in the majority of study participants, substance use was 
initiated prior to experiencing psychotic symptoms (17-20).  However, there are also findings 
referring to predominantly secondary onset of substance use after psychotic symptoms (21). 
In the present study, we aim to extend this area of inquiry by examining the association 
between use of three non-cannabinoid illegal drugs – cocaine, amphetamines and psychedelics – 
and psychotic symptoms.  We chose these specific illegal drugs because each of them has 
neurobiological underpinnings to psychosis.  For example, it has long been known that cocaine 
and amphetamines increase levels of dopamine by powerfully blocking the dopamine transporter 
(22-24).  While psychedelics are primarily serotonin-2A receptor agonists, lysergic acid 
diethylamide (LSD) in particular is known to have a high affinity for dopamine receptors 
(25,26).  It is not surprising, then, that substance intoxication with these substances includes 
psychotic symptoms such as paranoia and hallucinations. 
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Although elevated levels of psychotic symptoms among persons using cocaine or 
amphetamines have been reported in general population samples (14,16), clinical samples 
(12,13) and among prison inmates (15), the strength of the association has varied considerably.  
There are a number of limitations of studies on non-cannabinoid illegal drug use and 
psychotic symptoms.  First, studies using clinical or forensic samples are limited by selection 
bias (12,13,15).  Second, many studies have not adjusted for confounding variables such as other 
mental disorders, drug-induced psychosis, and use of cannabis or other drugs, such as opiates, 
sedatives, or PCP (13,14,16,17).   
Using data from a prospective-longitudinal community study of adolescents and young 
adults, we examine associations between cocaine, amphetamine or psychedelic use and psychotic 
symptoms.  Since psychotic symptoms can occur during the intoxication phase of these non-
cannabinoid drugs, we were specifically interested in examining whether these drugs were 
associated with psychotic symptoms that were not limited to the intoxication periods.  We 
predict that cocaine, amphetamine or psychedelic use will be associated with psychotic 
symptoms, independent of sociodemographic factors, adverse childhood experiences, and other 
drug (cannabis, opiates, sedatives, PCP) use, which are factors known to be associated with 
development of psychotic symptoms (27,28).  Due to methodological limitations, we were 
unable to examine temporal relationships between substance use and psychotic symptoms in this 
study.   
Aims of the study 
To examine the association between use of cocaine, amphetamine and psychedelics and 
psychotic symptoms in a large, representative community sample of adolescents and young 
adults followed over approximately 10 years.
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2. Methods 
2.1 Sample and overall design 
Data were collected as part of the Early Developmental Stages of Psychopathology 
(EDSP) study. The EDSP is a prospective-longitudinal study on prevalence, incidence, risk 
factors and course of substance use disorders and mental disorders in a representative community 
sample of adolescents and young adults (29,30). The baseline investigation was conducted in 
1995 with the total sample of 14- to 24-year-olds (N=3,021) and a response rate of 71%. The 
first follow-up study was conducted only among the younger cohort in 1996/1997 with a 
response rate of 88% among 14-17 year olds. The second follow-up (“4-year follow-up”) was 
carried out in 1998/1999 with a response rate of 84% among all 14- to 24-year-olds of the 
baseline investigation. The third follow-up (“10-year follow-up”) was also conducted among all 
participants in 2004/2005 and reached a response rate of 73%.  
The sample was randomly drawn from government registries in Munich, Germany. All 
participants provided informed consent after complete description of the study. Because the 
study was designed as a longitudinal panel with emphasis on the early developmental stages of 
psychopathology and substance use disorders, 14-15-year-olds were sampled at twice the 
probability of 16-21-year-olds, and four times the probability of 22-24-year-olds. The 
community sample has been demonstrated to be representative of the general population (29). 
 
2.2 Diagnostic Assessment 
Diagnostic assessments in all waves were based on the computer-assisted Munich-
Composite International Diagnostic Interview (M-CIDI/DIA-X, 31) which allows for the 
assessment of symptoms, syndromes, and diagnoses of 48 mental disorders according to the 
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DSM-IV criteria (32) and for collection of data on onset, duration, severity, and psychosocial 
impairment. Diagnostic findings were obtained by using the M-CIDI/DSM-IV algorithms. At 
baseline, the lifetime version of the M-CIDI was used. At each follow-up, the interval version 
was applied. In all assessments, the M-CIDI was supplemented by a respondents’ booklet that 
included scales and questionnaires for assessing psychological constructs relevant to the study 
(30). Interviews were conducted by trained clinical interviewers (mainly psychologists in 
postgraduate training) and closely monitored by the staff members and clinical supervisors 
during weekly supervision sessions. Correct interview administration was also verified by phone-
calls to participants. Follow-up interviews were conducted using the same procedures (29,30). 
Test-retest reliability and validity, which were fair to good (kappa 0.56-0.81 for DSM-IV 
diagnostic categories), have been reported in detail elsewhere (33,34). 
  
2.2.1 Assessment of substance use and substance use disorders 
The methods and previous results on substance use disorders of the study have been 
published in greater detail elsewhere (1,35-43).  Briefly, cocaine, amphetamines, and 
psychedelics and other illegal substance use (frequency and quantity), as well as DSM-IV abuse 
and dependence were assessed in Section L (drugs) of the M-CIDI/DIA-X. The section starts 
with screening questions on prescription drug use followed by questions on use of illegal 
substances. In the case of an affirmative response on the screening questions, a list of specific 
substances together with their “street-names” is presented. The list includes cocaine, 
amphetamines, and psychedelics, and five other classes of illegal substances (e.g. opioids, 
cannabis) as well as categories for “other” illegal substances and polysubstance use. Following 
this probe for the type of substance(s) used, questions are posed regarding the frequency and 
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quantity. If a respondent reports using any illegal substance 5 or more times, questions for each 
substance of these substances are posed in order to assess symptoms of DSM-IV abuse and 
dependence. The section is skipped for respondents who would not answer openly to questions 
about illegal substance use. Inter-rater reliability of the CIDI substance use, abuse and 
dependence sections is in the acceptable range (kappa 0.55-0.83 for DSM-IV diagnoses of abuse 
or dependence of a substance) and good agreement was found between clinician-assigned DSM-
IV substance use diagnoses and those assigned according to the M-CIDI DSM-IV algorithms 
(kappa 0.83-0.86 for DSM-IV diagnoses) (33,35).  In this study we refer to the lifetime use of 
cocaine, amphetamines and psychedelics five or more times. 
 
2.2.2 Assessment of psychotic symptoms 
 Psychotic symptoms were assessed in the Psychosis section (G) of the M-CIDI/DIA-X at 
4-year follow-up and 10-year follow-up.  At the 4-year follow-up, prior lifetime history of 
psychotic symptoms was assessed, whereas at 10-year follow-up, symptoms during the interval 
period were assessed.  A positive rating on any of the 15 core psychosis items of the M-CIDI 
(delusions, hallucinations) was regarded as a presence of a psychotic symptom.  Participants 
were questioned to ensure that none of the positive responses were due to direct effects of 
medication, drug or alcohol use.  The M-CIDI has been demonstrated to have a very low positive 
predictive value (0.226), a low specificity (0.6), a good negative predictive value (0.973) and 
sensitivity (0.875) for any specific psychotic disorder, such as schizophrenia (33).  For this 
reason, psychotic symptoms, and not disorders, were assessed.   This methodology has been 
utilized previously in epidemiologic work that has focused on examining the link between 
cannabis and psychosis (9). 
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2.3 Statistical analysis 
Data were weighted to consider different sampling probabilities as well as systematic 
non-response at baseline; numbers (N) are reported unweighted. The Stata 10.1 software package 
was used to calculate proportions and standard errors as well as robust confidence intervals for 
weighted data (44).  Cumulated data from baseline and all follow-up assessments are reported in 
this study.  Since the follow-up CIDI questions refer to the time since the last interview, 
aggregating the information from the different waves reflects the cumulative lifetime status up to 
the last completed assessment at 10-year follow-up (either 4-year or 10-year follow-up; the 
cohort aged 14-17 years at baseline was also assessed at 18 months).   
3021 participants completed the baseline assessment.  Of those, 2719 completed 4-year or 
10-year follow-up, the interviews in which psychotic symptoms were assessed.  131 participants 
refused to respond openly to the questions about illegal substance use on at least one assessment 
and were excluded leaving a sample of 2588 participants for our analyses. 
To examine associations between the three illegal drug groups and psychotic symptoms, 
multinomial logistic regression analyses were used, with psychotic symptoms as the outcome 
and use of cocaine, amphetamines and psychedelics as independent variables, where those using 
a specific drug five or more times were compared to those using that substance zero to four 
times.  First we report odds ratios (OR) and 95% confidence intervals (95% CI) from unadjusted 
logistic regression analyses.  Second, we report adjusted odds ratios (AOR).  Analyses were 
adjusted in two stages, first, for age, sex, social class, and urbanicity (Adjusted 1), and 
subsequently further adjusted for alcohol use disorder, nicotine dependence, cannabis use, other 
drug use disorder, any mood or anxiety disorder, and childhood adversity (Adjusted 2).  
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Childhood adversity included any qualifying trauma before the age of ten, death of a father or 
mother before the age of ten, separation or divorce of parents before the age of ten, or not 
growing up with biological parents for most of the time (all assessed at the baseline interview).  
Variables such as drug use disorders (2), mood or anxiety disorders (45,46), urbanicity (28) and 
childhood adversity (27) have been adjusted for in the analysis because they have been 
demonstrated to be associated with psychotic symptoms. 
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3. Results 
Table 1 provides the cumulative lifetime incidence estimates of cocaine, amphetamine or 
psychedelic use in the EDSP sample until the 10-year follow-up.  Additionally, it shows the 
distribution of sociodemographic factors and the cumulative incidence of substance use and 
specified mental disorders.  Of the 2588 participants included in our analysis (Table 1), 1319 
(number unweighted; percentage weighted: 49.5%) were male, and the mean age at last 
assessment was 27.1 years.  The cumulative incidence of lifetime cocaine use (five times or 
more) at 10-year follow-up was 5.5%, 6.3% for amphetamines, and 3.2% for psychedelics.  The 
cumulative lifetime incidence for any non-cannabinoid illegal substance (combined group of 
cocaine, amphetamines or psychedelics) use was 8.5%.   
At the last follow-up, the cumulative lifetime incidence of experiencing two or more 
psychotic symptoms was 218 (8.3%) for the total sample (N = 2588).  Among persons having 
used a substance five or more times, 32 (22.5%) experienced two or more psychotic symptoms 
for cocaine use, 37 (21.3%) for amphetamine use, 24 (28.2%) for psychedelics, and 49 (20.6%) 
for any non-cannabinoid illegal substance (combined group of cocaine, amphetamines or 
psychedelics) (Table 2).  The cumulative lifetime incidence of two or more psychotic symptoms 
did not differ between males (121, 8.9%, 95% CI 7.35-10.73) and females (97, 7.7%, 95% CI 
6.27-9.58).   
As shown in Table 3, a strong association was found between lifetime use of a substance 
and two or more psychotic symptoms in comparison to those without any psychotic symptoms 
(ORs ranging between 3.54-5.12).  Although adjusting for covariates decreased the size of the 
associations, the lifetime use of cocaine, psychedelics and use of any non-cannabinoid illegal 
substance (combined group of cocaine, amphetamine, psychedelics) remained significantly 
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associated with lifetime occurrence of two or more psychotic symptoms (AORs between 1.94-
2.37).  The association between amphetamine use and two or more psychotic symptoms did not 
remain significant after adjusting for covariates.  After adjusting for covariates, the associations 
between lifetime substance use and one psychotic symptom were not significant for any of the 
substances examined.   
In order to investigate whether the association between psychotic symptoms and 
substance use was independent of having a mood or anxiety disorder, we additionally performed 
subgroup analyses with data from all participants who had not met criteria for a mood or anxiety 
disorder during their lifetime (N = 1224). A strong association was found between lifetime use of 
a substance five or more times and two or more psychotic symptoms in comparison to those 
without psychotic symptoms (ORs ranging from 4.28-8.23, Table 4).  However, after adjusting 
for covariates, the association between lifetime substance use and two or more psychotic 
symptoms was significant only for psychedelics (OR 3.56, 95% CI 1.20-10.61).  Within this 
subgroup, none of the associations between lifetime substance use and one psychotic symptom 
remained significant after adjusting for covariates. 
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4. Discussion 
The main finding of the present study was that in adolescents and young adults, use of 
cocaine, amphetamine and/or psychedelics, was associated with psychotic symptoms.  These 
associations were significant when adjusted for variables known to increase risk for psychosis, 
and most associations also remained after adjustment for use of alcohol, nicotine, and cannabis.  
Our results extend the previous work (12,15-17) by showing an association between both 
psychedelics and stimulants (cocaine and amphetamine), and psychotic symptoms among a 
community-based population while excluding substance-induced psychosis.  Among the 
subgroup of people without a mood or anxiety disorder, the strength of associations between use 
of a substance and psychotic symptoms was similar for cocaine, amphetamine, and the combined 
group of substances, however, psychedelics showed a slightly stronger association that remained 
significant after adjusting for covariates. 
 
4.1 Strengths and Limitations 
Strengths of the study include a population-based sample not limited by selection bias 
associated with treatment-seeking samples, and measurement of symptoms based on a 
standardised interview conducted by psychologists.  Although community studies like the EDSP 
study data have some advantages in many ways, measurement of the outcomes is limited to 
psychotic symptoms (30).  Despite the remarkable prevalence of 8.5% for psychotic symptoms 
in this community survey, data could not be analysed for diagnostic outcomes such as 
schizophrenia, or another psychotic disorder, because the M-CIDI cannot validly assess 
psychotic disorders according to DSM-IV criteria (33).  Being based only on psychotic 
symptoms the results should not be interpreted as a positive association with psychosis in the 
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sense of diagnostic categories, as individual symptoms are more likely to occur than symptoms 
meeting a full set of criteria for a diagnosis of a disorder. The low prevalence of psychotic 
symptoms also limited our ability to perform a prospective analysis to examine whether a 
temporal relationship exists between substance use and psychotic symptoms.  It should be noted 
that the methodology used in the present study has been previously utilised and critically 
discussed in several other examinations on this topic with regard to cannabis disorders (6,9).  
Additionally, two other limitations have to be noted.  First, findings are based on self-reported 
use patterns and symptoms, which require accurate reports of the amount of a substance as well 
as accurate reports on symptoms.  As such, there is a possibility of recall bias, but the 
confidential interview method used may help to minimize recall errors and erroneous 
information.  Our study data assessed lifetime rates of substance use in a prospective, 
longitudinal design, which might account for somewhat elevated rates of substance use in 
comparison to some other studies, however, other population-based surveys, such as the National 
Household Survey on Drug Abuse found comparable estimates of substance use disorders.  
Among 12-29 year olds, 12-month rates of alcohol abuse were 27.4% and 14.5% for men and 
women, respectively, and 12.1% and 6.6% for alcohol dependence for men and women, 
respectively (47).  Second, this community sample comprises a relatively well-educated and 
economically stable urban population.  Therefore, estimates may not be generalisable to other 
more demographically diverse populations, and replication of findings in other community-based 
samples is needed. 
 
4.2 Clinical Relevance/Possible Implications 
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Several cases of adverse reactions to illegal substances, including death, have been 
reported, however, many individuals use them without harm, which may engender a false sense 
of security from adverse outcomes (48).  Illegal substance use and substance use disorders occur 
at a high rate among the population, especially among adolescents and young adults (3,17,38,41) 
and the co-occurrence between illegal substance use and psychosis is more prevalent than would 
be predicted by chance alone (20,49).  While the exact mechanisms underlying the occurrence of 
prolonged psychotic symptoms associated with non-cannabinoid substance use are not known, 
theories have been proposed.  There is some data to support a theory that repeated exposure to a 
stimulant, such as cocaine or amphetamines, leads to changes in the central nervous system, akin 
to ‘kindling’, implying that stimulant use may cause a psychosis that would not have occurred in 
the absence of the stimulant (50).  There is less research in the area of prolonged psychotic 
symptoms associated with psychedelic use, however, a model where use of psychedelics might 
be associated with accelerating or precipitating the onset of an illness that would have ultimately 
have developed in an individual, has been proposed (51). 
 Because of conflicting evidence showing that substance use may begin before or after the 
onset of psychotic symptoms, studies examining the biochemical interactions and possible 
genetic factors at play will be important in proving or disproving the etiologic theories proposed.  
Studies examining genetic factors have begun in the areas of cannabis-psychosis association with 
examination of the catechol-O-methyltransferase gene (52) and methamphetamine-psychosis 
association with examination of protein interacting with C kinase (PICK1) gene (53) and 
polymorphisms therein that may modulate clinical outcomes after exposure to those substances.  
Similar genetic links associated with development of psychosis in individuals using other non-
cannabis substances should be investigated, in addition to further elucidating non-biologic 
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factors such as environmental influences.  Ongoing advances in neuroimaging such as diffusion 
tensor imaging (54) may also prove valuable in identifying structural abnormalities in many 
psychiatric disorders and possibly abnormalities common to both psychotic and substance use 
disorders. 
 In conclusion, findings from this study contribute to a growing body of literature that 
suggests that use of non-cannabinoid drugs such as cocaine, amphetamines or psychedelics is 
associated with psychotic symptoms.  While neither the causality nor the possible biochemical 
mechanisms underlying this association have yet been demonstrated, this nonetheless presents a 
significant public health concern and the potential to utilize public education to reduce drug use 
and cases of psychosis in young adults should be carefully considered.  Nonetheless, there 
remains a further need for longitudinal data in order to clarify the temporal sequence and 
whether substance use is, in fact, a causal factor in experiencing psychotic symptoms. 
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